These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1041 related articles for article (PubMed ID: 19444550)
21. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients. Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390 [TBL] [Abstract][Full Text] [Related]
22. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers. Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710 [TBL] [Abstract][Full Text] [Related]
23. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Bogaert J; Maes A; Deneffe GJ; Nackaerts KL; Verschakelen JA; Lerut TE; Mortelmans LA; Demedts MG J Clin Oncol; 1998 Jun; 16(6):2142-9. PubMed ID: 9626214 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of (18)F-FDG PET/CT for lymph node staging in patients with operable non-small-cell lung cancer and inflammatory lung disease. An YS; Sun JS; Park KJ; Hwang SC; Park KJ; Sheen SS; Lee S; Lee KB; Yoon JK Lung; 2008; 186(5):327-36. PubMed ID: 18670805 [TBL] [Abstract][Full Text] [Related]
25. The clinical value of F-18 FDG PET/CT in differentiating malignant from benign lesions in pneumoconiosis patients. Choi EK; Park HL; Yoo IR; Kim SJ; Kim YK Eur Radiol; 2020 Jan; 30(1):442-451. PubMed ID: 31338654 [TBL] [Abstract][Full Text] [Related]
26. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Nakayama M; Okizaki A; Ishitoya S; Sakaguchi M; Sato J; Aburano T Ann Nucl Med; 2013 Feb; 27(2):163-9. PubMed ID: 23188388 [TBL] [Abstract][Full Text] [Related]
27. A Pilot Study of Zhou Y; Gao S; Huang Y; Zheng J; Dong Y; Zhang B; Zhao S; Lu H; Liu Z; Yu J; Yuan S Sci Rep; 2017 Jun; 7(1):2877. PubMed ID: 28588317 [TBL] [Abstract][Full Text] [Related]
28. [Preliminary study of 18F-FDG PET-CT in defining lymph node radiation target volume for non-small-cell lung cancer patients]. Liu LP; Yu JM; Guo HB; Fu Z; Han AQ; Yang GR Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):453-6. PubMed ID: 17974282 [TBL] [Abstract][Full Text] [Related]
29. Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer. Kwon SY; Kim J; Jung SH; Chong A; Song HC; Bom HS; Min JJ Clin Nucl Med; 2016 Jan; 41(1):e32-8. PubMed ID: 26164179 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387 [TBL] [Abstract][Full Text] [Related]
31. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT. Wang Y; Ma S; Dong M; Yao Y; Liu K; Zhou J BMC Pulm Med; 2015 Mar; 15():20. PubMed ID: 25880540 [TBL] [Abstract][Full Text] [Related]
33. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study. Nguyen NC; Kaushik A; Wolverson MK; Osman MM Acta Oncol; 2011 Jun; 50(5):670-7. PubMed ID: 21247262 [TBL] [Abstract][Full Text] [Related]
34. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841 [TBL] [Abstract][Full Text] [Related]
35. Improving diagnostic performance of Yang DD; Mirvis E; Goldring J; Patel ARC; Wagner T Clin Radiol; 2019 Oct; 74(10):818.e17-818.e23. PubMed ID: 31420186 [TBL] [Abstract][Full Text] [Related]
37. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET]. Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018 [TBL] [Abstract][Full Text] [Related]
38. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. Mattes MD; Moshchinsky AB; Ahsanuddin S; Rizk NP; Foster A; Wu AJ; Ashamalla H; Weber WA; Rimner A Clin Lung Cancer; 2015 Nov; 16(6):e253-8. PubMed ID: 26163919 [TBL] [Abstract][Full Text] [Related]
39. Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer. Wumener X; Zhang Y; Wang Z; Zhang M; Zang Z; Huang B; Liu M; Huang S; Huang Y; Wang P; Liang Y; Sun T Front Oncol; 2022; 12():1005924. PubMed ID: 36439506 [TBL] [Abstract][Full Text] [Related]
40. Prognostic importance of Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]